MHRA paediatric investigation plan
Not available at present (Live, attenuated, dengue virus, serotype 1 (DENV1))
MHRA paediatric investigation plan MHRA-100096-PIP01-21 · Agreement
Key facts
| PIP number | MHRA-100096-PIP01-21 |
|---|---|
| Product names | Not available at present |
| Active substances | Live, attenuated, dengue virus, serotype 1 (DENV1), Live, attenuated, chimeric dengue virus, serotype 2 (DENV2), Live, attenuated, dengue virus, serotype 3 (DENV3), Live, attenuated, dengue virus, serotype 4 (DENV4) |
| Therapeutic areas | Vaccines |
| Conditions | Prevention of dengue disease |
| Decision | P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) |
| Published | Dec 19, 2023 |
| MHRA record | cms.mhra.gov.uk |
About MHRA paediatric investigation plans
A paediatric investigation plan sets out the studies a company must run in children to support authorisation of a medicine in the UK, or records a waiver or deferral.
Source: UK Medicines and Healthcare products Regulatory Agency (MHRA). Contains public sector information licensed under the Open Government Licence v3.0 · Source date: